Study: US drugs not reviewed equally

2014-01-22 16:47

(Shutterstock)

Multimedia   ·   User Galleries   ·   News in Pictures Send us your pictures  ·  Send us your stories

Washington - Consumers may expect that medical treatments approved for the US market are safe and thoroughly tested, but a study out on Tuesday said that is not always the case.

Some drugs undergo more rigorous testing than others, while most are never compared to existing treatments to see if they are better or worse, said the study by researchers at Yale University.

The study in the Journal of the American Medical Association reviewed the process by which 188 new therapies were accepted for US market by the Food and Drug Administration over a seven-year span.

Around 37% were allowed on the market based on the results of a single trial that was never replicated or confirmed.

Fewer than half were compared to treatments already on the market.

"Many other trials were small, short, and focused on lab values, or some other surrogate metric of effect, rather than clinical endpoints like death", said first author and Yale School of Medicine student Nicholas Downing.

Although patients may think that doctors only dole out safe and effective medicines, a closer look at the FDA process raised doubts, said Downing.

Differing standards

"Based on our study of the data, we can't be certain that this expectation is necessarily justified, given the quantity and quality of the variability we saw in the drug approval process", he said.

In some cases, the FDA's "regulatory flexibility" can pave the way for faster approval of "potentially effective therapies for life-threatening diseases, such as certain cancers, or those diseases for which there is no existing effective treatment", said the study.

To insist that all drugs meet the same standard could result in higher costs and longer wait times.

Still, researchers said the public and the regulatory community should be aware of the vastly differing standards for market approval.

"Based on our analysis, some drugs are approved on the basis of large, high-quality clinical trials, while others are approved based on results of smaller trials", said senior author Joseph Ross, assistant professor of internal medicine at Yale School of Medicine.

"There was a lack of uniformity in the level of evidence the FDA used."

The FDA does not require data on comparative effectiveness as part of its approval process, the Jama study noted.

Ross said only 40% of drug approvals involved a clinical trial that compared one new drug to another, which he described as "an important step for determining whether the new drug is a better option than existing, older drugs".

The researchers described their work as the first systematic analysis of the standard used by the FDA in making drug approval decisions.

Read more on:    fda  |  yale  |  us  |  health

Join the conversation!

24.com encourages commentary submitted via MyNews24. Contributions of 200 words or more will be considered for publication.

We reserve editorial discretion to decide what will be published.
Read our comments policy for guidelines on contributions.

24.com publishes all comments posted on articles provided that they adhere to our Comments Policy. Should you wish to report a comment for editorial review, please do so by clicking the 'Report Comment' button to the right of each comment.

Comment on this story
2 comments
Comments have been closed for this article.

Inside News24

 
/News

Book flights

Compare, Book, Fly

Traffic Alerts
Traffic
There are new stories on the homepage. Click here to see them.
 
English
Afrikaans
isiZulu

Hello 

Create Profile

Creating your profile will enable you to submit photos and stories to get published on News24.


Please provide a username for your profile page:

This username must be unique, cannot be edited and will be used in the URL to your profile page across the entire 24.com network.

Settings

Location Settings

News24 allows you to edit the display of certain components based on a location. If you wish to personalise the page based on your preferences, please select a location for each component and click "Submit" in order for the changes to take affect.




Facebook Sign-In

Hi News addict,

Join the News24 Community to be involved in breaking the news.

Log in with Facebook to comment and personalise news, weather and listings.